Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Gain Therapeutics's total assets was $15.42M at Jun 30, 2026. For fiscal 2025 it was $22.82M, up 88.2% from the year before. The highest annual figure on record is $38.99M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.82M | +88.2% |
| FY2024 | Dec 31, 2024 | $12.12M | -34.9% |
| FY2023 | Dec 31, 2023 | $18.61M | -22.8% |
| FY2022 | Dec 31, 2022 | $24.10M | -38.2% |
| FY2021 | Dec 31, 2021 | $38.99M | +305.9% |
| FY2020 | Dec 31, 2020 | $9.60M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.42M | +56.8% |
| Q1 FY2026 | Mar 31, 2026 | $18.74M | +61.2% |
| Q4 FY2025 | Dec 31, 2025 | $22.82M | +88.2% |
| Q3 FY2025 | Sep 30, 2025 | $10.97M | -23.6% |
| Q2 FY2025 | Jun 30, 2025 | $9.83M | -48.8% |
| Q1 FY2025 | Mar 31, 2025 | $11.62M | -20.3% |
| Q4 FY2024 | Dec 31, 2024 | $12.12M | -34.9% |
| Q3 FY2024 | Sep 30, 2024 | $14.37M | +1.9% |
| Q2 FY2024 | Jun 30, 2024 | $19.20M | +5.1% |
| Q1 FY2024 | Mar 31, 2024 | $14.58M | -31.6% |
| Q4 FY2023 | Dec 31, 2023 | $18.61M | -22.8% |
| Q3 FY2023 | Sep 30, 2023 | $14.10M | -50.2% |
| Q2 FY2023 | Jun 30, 2023 | $18.26M | -42.7% |
| Q1 FY2023 | Mar 31, 2023 | $21.32M | -43.3% |
| Q4 FY2022 | Dec 31, 2022 | $24.10M | -38.2% |
| Q3 FY2022 | Sep 30, 2022 | $28.33M | -33.4% |
| Q2 FY2022 | Jun 30, 2022 | $31.89M | -29.7% |
| Q1 FY2022 | Mar 31, 2022 | $37.60M | -21.7% |
| Q4 FY2021 | Dec 31, 2021 | $38.99M | +305.9% |
| Q3 FY2021 | Sep 30, 2021 | $42.56M | – |
| Q2 FY2021 | Jun 30, 2021 | $45.35M | – |
| Q1 FY2021 | Mar 31, 2021 | $48.04M | – |
| Q4 FY2020 | Dec 31, 2020 | $9.60M | – |
See a number that looks wrong?